[Coping with pathological changes in nerves and blood vessels in collagen disease--CNS lupus].
Hirohata
S
S
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D002493:Central Nervous System Diseases / Q000175:diagnosis / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000134:cerebrospinal fluid; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016898:Interferon-alpha / Q000134:cerebrospinal fluid; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000209:etiology; D011619:Psychotropic Drugs / Q000627:therapeutic use; D013256:Steroids
D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D015415:Biomarkers; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D015850:Interleukin-6; D011619:Psychotropic Drugs; D013256:Steroids; D003520:Cyclophosphamide